Phase 1 Parkinson’s Disease Studies Show the Dopamine D1/D5 Agonist PF-06649751 is Safe and Well Tolerated

INTRODUCTION: There is a need for new therapies in Parkinson’s disease that may help to address known limitations of current options. PF-06649751 is a novel, highly selective dopamine D1/D5 agonist targeted for Parkinson’s disease treatment. METHODS: The safety, pharmacokinetics, and pharmacodynamic...

Descripción completa

Detalles Bibliográficos
Autores principales: Sohur, U. Shivraj, Gray, David L., Duvvuri, Sridhar, Zhang, Yao, Thayer, Kathleen, Feng, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283789/
https://www.ncbi.nlm.nih.gov/pubmed/30361858
http://dx.doi.org/10.1007/s40120-018-0114-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6283789/
https://www.ncbi.nlm.nih.gov/pubmed/30361858
http://dx.doi.org/10.1007/s40120-018-0114-z

Ejemplares similares